文献速递免疫规划

通过比较体外与体内数据预测鸡高致病性禽流感疫苗效力:一项Meta分析与系统综述

Prediction of highly pathogenic avian influenza vaccine efficacy in chickens by comparison of in vitro and in vivo data: A meta-analysis and systematic review.
PubMed 文献 · Vaccine · 2023-08-01

该系统综述与Meta分析纳入25篇文献的120项独立试验,评估油佐剂灭活全病毒疫苗、重组火鸡疱疹病毒(rHVT)载体疫苗和非复制型α病毒载体RNA颗粒(RP)疫苗在鸡高致病性禽流感攻毒模型中的保护效果,发现疫苗诱导的针对攻毒病毒抗体滴度(VIAC)越高,各平台疫苗的排毒减少和效力越好。

要点

  • 针对攻毒病毒的抗体滴度(VIAC)越高,各平台疫苗的排毒减少和效力越好。
  • 灭活疫苗和rHVT载体疫苗中,HA1相关性与VIAC越高,存活越好。
  • rHVT和RP疫苗对HA1变异更耐受,rHVT疫苗HA1相关性与存活无显著相关。

核心结论

  • 针对攻毒病毒的疫苗诱导抗体滴度(VIAC)越高,所有疫苗平台的排毒减少和效力越好。
  • HA1相关性和使用攻毒病毒作为抗原的VIAC越高,与灭活疫苗和rHVT载体疫苗的更好存活相关。
  • rHVT载体疫苗和RP疫苗对HA1变异更耐受;rHVT疫苗的HA1相关性与存活无显著相关。
  • 在有数据的最低氨基酸相似度下即达到保护:rHVT疫苗为90-93%,RP疫苗为88%。

研究设计与样本

  • 系统综述与Meta分析,纳入25篇文献共120项独立试验,评估鸡高致病性禽流感攻毒后的疫苗效力数据。
  • 评估三种疫苗平台:油佐剂灭活全禽流感病毒疫苗、重组火鸡疱疹病毒(rHVT)载体疫苗、非复制型α病毒载体RNA颗粒(RP)疫苗。
  • 疫苗标准为:疫苗抗原与攻毒株在血凝素1结构域(HA1)蛋白序列的相关性;疫苗诱导的针对攻毒病毒的抗体滴度(VIAC)。
  • 保护指标为:免疫鸡与未免疫对照的存活比较;免疫鸡与未免疫对照在攻毒后2-4天口腔排毒的减少比较。

主要发现

  • 针对攻毒病毒的VIAC越高,所有疫苗平台的排毒减少和疫苗效力越好。
  • 使用攻毒病毒作为抗原时,HA1相关性越高和VIAC越高,与灭活疫苗和rHVT载体疫苗的更好存活相关。
  • rHVT载体疫苗和RP疫苗对HA1变异更耐受;rHVT疫苗的HA1相关性与存活无显著相关。
  • 在有数据的最低氨基酸相似度下达到保护:rHVT疫苗为90-93%,RP疫苗为88%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccines for avian influenza (AI) can protect poultry against disease, mortality, and virus transmission. Numerous factors, including: vaccine platform, immunogenicity, and relatedness to the field strain, are known to be important to achieving optimal AI vaccine efficacy. To better understand how these factors contribute to vaccine protection, a systematic meta-analysis was conducted to evaluate efficacy data for vaccines in chickens challenged with highly pathogenic (HP) AI. Data from a total of 120 individual trials from 25 publications were selected and evaluated. Two vaccine criteria were evaluated for their effects on two metrics of protection. The vaccine criteria were: 1) the relatedness of the vaccine antigen and challenge strain in the hemagglutinin 1 domain (HA1) protein sequence; 2) vaccine-induced antibody titers to the challenge virus (VIAC). The metrics of protection were: A) survival of vaccinated chickens vs unvaccinated controls; and B) reduction in oral virus-shedding by vaccinated vs unvaccinated controls 2-4 days post challenge. Three vaccine platforms were evaluated: oil-adjuvanted inactivated whole AI virus, recombinant herpes virus of turkeys (rHVT) vectored, and a non-replicating alpha-virus vectored RNA particle (RP) vaccine. Higher VIAC correlated with greater reduction of virus-shed and vaccine efficacy by all vaccine platforms. Both higher HA1 relatedness and higher VIAC using challenge virus as antigen correlated with better survival by inactivated vaccines and rHVT-vectored vaccines. However, rHVT-vectored and RP based vaccines were more tolerant of variation in the HA1; the relatedness of the HA1 of the vaccine and challenge virus did not significantly correlate with survival with rHVT-vectored vaccines. Protection was achieved with the lowest aa similarity for which there was data, 90-93 % for rHVT vaccines and 88 % for the RP vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mo J, Spackman E, Swayne DE, et al. Prediction of highly pathogenic avian influenza vaccine efficacy in chickens by comparison of in vitro and in vivo data: A meta-analysis and systematic review. Vaccine. 2023. PMID: 37537093. doi:10.1016/j.vaccine.2023.07.076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。